Angiogenesis (also known as neovascularization) is the generation of new blood vessels from pre-existing vasculature. It is a normal process in growth and development and is required for the formation of arteries, veins, and capillaries in an embryo. Proliferation of new blood vessels also takes place in adults and is essential for the repair or regeneration of tissue during wound healing.
Angiogenesis Product Areas
Aberrant angiogenesis is a critical event in tumorigenesis. As a tumor develops, its volume and size is limited by the availability of oxygen, glucose and other necessary metabolites from the existing vasculature. In order to maintain growth, new blood vessels are necessary to meet the metabolic demands of the tumor.
As the tumor grows and metabolic demands increase, it becomes hypoxic at the centre. Expression of the transcription factor hypoxia inducible factor-1 (HIF-1) is induced, which in turn induces expression of several angiogenic factors. These include vascular-endothelial growth factor (VEGF), fibroblast growth factor (FGF), protein kinase G, angiopoietins and matrix metalloproteases.
Establishment of tumor angiogenesis is a critical event in the development, growth and metastasis of cancers. Development of antiangiogenic pharmacological agents is an intense area of cancer research.
Find multiple products by catalog number
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.